Although a large number of new agents targeting the EGFR pathways are being tested and have shown certain efficacy through greater survival in clinical and pre-clinical models, it remains unclear as to how combination EGFR therapy with chemotherapy will impact breast cancer patients. Here, EGFR is linked to breast cancer.